Clinical Trial Update: Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial update suggests IQP-VV-102 reduces postprandial glucose in overweight Caucasian subjects. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperglycemia
• Prediabetes

Drugs mentioned

• IQP-VV-102

Snippet

Sponsor: InQpharm Group | Conditions: Prediabetes, Hyperglycemia | Phase 3 | Status: COMPLETED